Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

Background and Aims: Fibrolamellar carcinoma (FLC) is a rare, difficult-to-treat liver cancer primarily affecting pediatric and adolescent patients, and for which precision medicine approaches have historically not been possible. The DNAJB1-PRKACA gene fusion was identified as a driver of FLC pathog...

Full description

Bibliographic Details
Main Authors: Stefanie S. Schalm, Erin O’Hearn, Kevin Wilson, Timothy P. LaBranche, Grace Silva, Zhuo Zhang, Lucian DiPietro, Neil Bifulco, Richard Woessner, Nicolas Stransky, Darshan Sappal, Robert Campbell, Riadh Lobbardi, Michael Palmer, Joseph Kim, Chaoyang Ye, Marion Dorsch, Christoph Lengauer, Timothy Guzi, Vivek Kadambi, Andrew Garner, Klaus P. Hoeflich
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Gastro Hep Advances
Subjects:
Fibrolamellar carcinoma
PRKACA
DNAJB1-PRKACA
Kinase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2772572322001911

Internet

http://www.sciencedirect.com/science/article/pii/S2772572322001911

Similar Items